Robotic Radiotherapy Market Size & Share 2026-2035

Robotic Radiotherapy Market Size

The robotic radiotherapy market was valued at USD 1.35 billion in 2025, is estimated at USD 1.50 billion in 2026, is projected to grow at an 11.0% CAGR (2026–2035), and is expected to reach USD 3.83 billion by 2035. The market comprises precision-guided radiation therapy systems, associated imaging and tracking modules, treatment-planning software, and related services that combine robotic positioning, automation, and image guidance for oncology care.

Market expansion reflects a transition from conventional radiation delivery toward adaptive, stereotactic, and motion-managed treatment pathways. Replacement demand for earlier-generation equipment is increasingly paired with investments in software-enabled workflow upgrades, allowing providers to add clinical capability while managing the operational disruption associated with major capital installations.

Robotic Radiotherapy Market Trends, Growth Drivers & GMI Forecast Outlook

Demand is being shaped by rising oncology treatment volumes, the clinical migration toward stereotactic and adaptive protocols, and the need to improve throughput from constrained treatment capacity. The addressable opportunity is strongest where equipment replacement, reimbursement support, specialist availability, and software-enabled workflow modernization align.

Key Drivers

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Cancer incidence is enlarging the long-term patient pool for radiation oncology services. IARC projects that annual global cancer cases could reach 34.4 million by 2050, reinforcing the need for treatment capacity that can manage both higher case volumes and more complex disease presentations ^{[1]International Agency for Research on Cancer. "Global Cancer Statistics 2024: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 34 Cancers in 186 Countries." iarc.who.int}. For providers, robotic systems are relevant not simply as equipment purchases, but as a means to expand precision-treatment capacity within existing oncology networks.

The investment case is increasingly framed around clinical productivity and longitudinal service delivery. Public health systems and large provider groups are using multi-year technology partnerships to coordinate imaging, treatment delivery, planning software, and professional services, as illustrated by Siemens Healthineers' adaptive-radiotherapy partnership expansion with Prisma Health ^{[3]Siemens Healthineers. "Siemens Healthineers, Prisma Health Expand Value Partnership with $50 Million Investment in Radiation Therapy." siemens-healthineers.com}. In parallel, adaptive planning, real-time tracking, and hypofractionated protocols improve the commercial relevance of software and imaging functionality after the initial system sale.

Key Restraints

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Workforce capacity remains a practical constraint on the conversion of clinical need into installed-system demand. Robotic platforms require radiation oncologists, medical physicists, technologists, quality-assurance processes, and sufficiently mature treatment workflows. Financing can make a system more accessible, but it cannot quickly resolve shortages in specialist training or commissioning capability.

The effect differs by market maturity. Established oncology centers may defer capacity activation because staffing limits protocol expansion and quality assurance, while emerging systems may lack the specialist base required to operate advanced equipment safely and consistently. Capital costs and divergent regulatory requirements compound this challenge by raising both the financial and administrative threshold for adoption.

Robotic Radiotherapy Market Segment Analysis

By Product

Radiotherapy Systems

Radiotherapy systems accounted for 60.0% of the robotic radiotherapy market in 2025 and are projected to generate USD 2.20 billion by 2035. Their continuing prominence reflects the capital value of integrated treatment platforms, including robotic linac, radiosurgery, and particle-therapy configurations. The category remains central to oncology capital budgets because providers need treatment delivery, imaging, and patient-positioning capability to function as a coordinated clinical system. However, bundled procurement is gradually shifting the revenue mix toward complementary software, analytics, and service relationships that extend beyond the original installation.

Software generated USD 337 million in 2025 and is expected to expand at a 13.5% CAGR (2026–2035). Demand is concentrated in treatment planning, workflow management, dose calculation, quality assurance, and adaptive-treatment applications. Its growth is tied to the ability of providers to add planning and automation capability to compatible installed hardware. This creates a recurring commercial relationship for vendors while allowing facilities to pursue clinical upgrades without waiting for a full equipment replacement cycle.

3D Cameras & Imaging

3D cameras and imaging represented 10.0% of market revenue in 2025 and are projected to reach USD 383 million by 2035. These modules support surface guidance, cone-beam imaging, and real-time tracking within robotic treatment workflows. Their strategic role is increasingly defined by the need to verify positioning and manage intra-fraction motion during high-precision treatment. As stereotactic protocols become more widely adopted, imaging is moving from an adjunctive component toward a core enabling layer of treatment delivery.

Other Products

Other products accounted for 5.0% of the market in 2025 and are projected to generate USD 159 million by 2035. This group includes robotic accessories, multi-leaf collimator upgrades, and ancillary system components. Demand is influenced by the installed base and by how vendors structure service and replacement packages. Standalone component purchases may become less visible as suppliers increasingly embed upgrades within longer-term system and maintenance agreements.

By Technology

Linear Accelerators (LINAC)

LINAC platforms held a 40.0% market share in 2025 and are projected to account for 35.3% by 2035. Their installed-base depth, broad clinical versatility, and established service infrastructure sustain their importance across hospital and cancer-center settings. The relative mix shift does not imply reduced relevance. Rather, it reflects a broader technology portfolio in which stereotactic, adaptive, proton, and particle platforms capture a larger share of incremental investment for selected clinical use cases.

Stereotactic Radiotherapy (SRT/SBRT)

SRT/SBRT systems generated USD 297 million in 2025 and are projected to reach USD 964 million by 2035. Their commercial position is supported by expanding use in precision treatment pathways for localized and oligometastatic disease. Demand is reinforced by the operational appeal of shorter treatment courses and by the need for integrated tracking, motion management, and dose-conformity capabilities. Providers evaluating specialized oncology programs increasingly view stereotactic capability as both a clinical differentiator and a utilization-enhancing investment.

CyberKnife

CyberKnife accounted for 18.0% of the market in 2025 and is projected to represent 18.2% by 2035. The platform retains a defined role in frameless robotic radiosurgery and treatment settings where continuous target tracking is a priority. Its stability reflects a mature clinical niche rather than a broad replacement of other modalities. Continued relevance will depend on installed-base upgrades, service support, and the ability to preserve differentiation in cranial, spinal, and extracranial applications.

Gamma Knife

Gamma Knife generated USD 108 million in 2025 and is projected to hold 6.8% of the market by 2035. The technology remains strongly associated with intracranial radiosurgery and specialized neurosurgical treatment programs. Its narrower anatomical focus limits its addressable market relative to multipurpose platforms, but that focus also supports a durable role in centers with established radiosurgery pathways. The installed base provides an important foundation for service and upgrade demand.

Proton Beam Therapy

Proton beam therapy accounted for 7.0% of the market in 2025 and is projected to generate USD 319 million by 2035. Investment is concentrated in clinical settings where dose-sparing characteristics are valued for complex tumors and sensitive anatomical sites. The market's development is closely tied to efforts to lower facility footprint and infrastructure requirements. Compact and single-room configurations can broaden the prospective customer base beyond the largest academic centers, although capital intensity remains a significant adoption barrier.

Heavy Ion / Particle Therapy

Heavy ion and particle therapy represented 3.0% of the market in 2025 and is anticipated to grow at a 14.0% CAGR (2026–2035). The category is supported by national programs and specialized centers pursuing treatment options for radio-resistant tumors. Commercial adoption will remain highly selective because these platforms require substantial clinical, engineering, and financing capability. Their growth outlook is strongest where national health priorities, research infrastructure, and long-term facility investment converge.

Other Technologies

Other technologies accounted for 2.0% of the market in 2025 and are projected to generate USD 70 million by 2035. This category includes MR-linac hybrids, PET-guided treatment systems, and early-commercial AI-integrated delivery platforms. These technologies illustrate the direction of product development toward more information-rich treatment delivery. Their wider adoption will depend on clinical validation, reimbursement alignment, workflow integration, and the pace of regulatory clearance.

By Application

Prostate Cancer

Prostate cancer represented 22.0% of the market in 2025 and is projected to generate USD 882 million by 2035. It is a leading application because precise target coverage and protection of adjacent organs make image guidance and motion management commercially valuable. Hypofractionated treatment pathways strengthen the case for robotic capability in this indication. Providers can position precision, patient convenience, and treatment efficiency together when evaluating advanced systems for prostate-focused oncology programs.

Breast cancer generated USD 270 million in 2025 and is projected to account for 18.9% of the market by 2035. Demand spans partial-breast irradiation, whole-breast treatment, and regional nodal applications requiring accurate target shaping and positioning. The clinical proposition centers on reproducibility, surface guidance, and management of cardiac and pulmonary exposure. Adoption will be influenced by the degree to which providers integrate these capabilities into shorter-course and personalized-treatment protocols.

Lung Cancer

Lung cancer accounted for 18.0% of market revenue in 2025 and is expected to grow at a 12.0% CAGR (2026–2035). The application is a major driver of demand for respiratory-motion management, beam synchronization, and real-time imaging. Lung treatment highlights why robotic precision matters operationally as well as clinically. Systems that can manage free-breathing targets and support high-dose stereotactic delivery are positioned to benefit as providers broaden treatment options for medically complex patients.

Head & Neck Cancer

Head and neck cancer generated USD 202 million in 2025 and is projected to reach USD 548 million by 2035. The indication supports demand for adaptive approaches that can account for anatomical changes during multi-week treatment courses. Online replanning and soft-tissue imaging are particularly relevant because tumor regression and changes in surrounding structures can affect dose distribution. This makes adaptive capability a meaningful differentiator for providers treating complex head and neck cases.

Colorectal Cancer

Colorectal cancer represented 10.0% of the market in 2025 and is projected to generate USD 383 million by 2035. Robotic systems are increasingly relevant where abdominal target motion and bowel-dose constraints require accurate planning and delivery. The opportunity is linked to treatment pathways for locally advanced rectal disease and selected metastatic settings. Providers value systems that combine motion management with planning flexibility when treating anatomically variable targets.

Other Applications

Other applications generated USD 201 million in 2025 and are projected to reach USD 571 million by 2035. The category includes CNS malignancies, gynecologic cancers, bone metastases, and selected functional radiosurgery uses. These indications reinforce the breadth of demand for sub-millimeter accuracy, especially where critical structures limit the therapeutic margin. Clinical expansion in this group can create incremental demand for specialized planning, tracking, and radiosurgery capability.

By End Use

Hospitals

Hospitals accounted for 60.0% of the market in 2025 and are projected to generate USD 2.10 billion by 2035. Their leadership reflects the concentration of high-capital equipment in tertiary oncology departments and academic medical centers. Hospitals retain advantages in clinical staffing, patient volumes, and infrastructure, although procurement is subject to competing capital priorities. Their future role will depend on how effectively health systems connect equipment replacement with digital workflow and service strategies.

Cancer Treatment Centers

Cancer treatment centers generated USD 297 million in 2025 and are projected to reach USD 922 million by 2035. Independent and networked oncology facilities are using advanced radiotherapy capability to support complex-case referrals and outpatient care models. These centers are well positioned to benefit from shorter-course treatment protocols because efficient scheduling can improve patient experience and asset utilization. Their expansion also broadens the market beyond traditional hospital-led procurement.

Academic & Research Institutes

Academic and research institutes represented 12.0% of the market in 2025 and are projected to generate USD 460 million by 2035. These institutions serve both as treatment providers and as early adopters of novel radiotherapy technologies. Their purchasing decisions often influence broader clinical confidence in new modalities. Research-led deployments can establish the evidence base, training ecosystem, and workflow experience that support subsequent adoption in community oncology settings.

Specialty Clinics

Specialty clinics accounted for 6.0% of the market in 2025 and are projected to grow at a 13.5% CAGR (2026–2035). Demand is supported by compact platforms that can make advanced radiosurgery more practical for focused oncology and neurosurgical programs. The segment's development depends on whether suppliers can reduce infrastructure barriers while maintaining the clinical and quality-assurance standards required for high-precision treatment. In urban private-care markets, these systems can enable specialized facilities to differentiate their service offering.

Robotic Radiotherapy Market Regional Analysis

North America Robotic Radiotherapy Market Analysis

North America generated USD 472 million in 2025 and is projected to reach USD 1.34 billion by 2035. The robotic radiotherapy market in the region is supported by a deep installed base, established reimbursement frameworks, and a concentration of academic medical centers, health systems, and community oncology networks. Replacement demand is likely to remain important as providers seek adaptive planning, workflow automation, and advanced stereotactic capability. Procurement is also supported by a comparatively mature service ecosystem, although staffing constraints and payer requirements can lengthen investment timelines.

U.S.

The U.S. generated USD 404 million in 2025 and is projected to reach USD 1.15 billion by 2035. Demand is anchored by hospital-based departments and outpatient oncology settings pursuing upgrades to adaptive-capable treatment platforms. The market benefits from established device-clearance pathways and broad clinical adoption of precision radiotherapy. System refresh cycles and the movement of selected treatments into outpatient pathways should sustain demand for integrated hardware, software, and service offerings.

Canada

Canada accounted for 14.4% of North American revenue in 2025 and is projected to generate USD 192 million by 2035. Provincial cancer-care investment and academic clinical programs provide the foundation for equipment modernization. Public procurement cycles can be lengthy, but coordinated capital planning can create visibility for suppliers. Demand will favor systems that fit provincial care networks and can be supported by the available specialist workforce.

Europe Robotic Radiotherapy Market Analysis

Europe accounted for 28.0% of the market in 2025 and is projected to generate USD 1.07 billion by 2035. The robotic radiotherapy market across Europe is shaped by national infrastructure programs, advanced academic treatment networks, and a varied mix of public and private reimbursement models. Adoption rates differ materially by country because funding models, workforce availability, and equipment renewal cycles are not uniform. The region's regulatory framework can support multi-country commercialization, but compliance and procurement complexity remain important commercial considerations.

Germany

Germany represented 21.4% of European revenue in 2025 and is projected to reach USD 230 million by 2035. Its position reflects strong university-hospital infrastructure and a long-standing role in particle-therapy and advanced-radiotherapy research. The market is supported by specialized centers with the capability to assess and operate complex technologies. This environment favors vendors with clinical evidence, service capacity, and products that can be incorporated into established treatment networks.

U.K.

The U.K. accounted for 17.7% of European revenue in 2025 and is projected to generate USD 191 million by 2035. National radiotherapy modernization initiatives and private oncology investment support demand for advanced systems. Staffing pressure can slow the pace at which equipment is commissioned and fully utilized. As a result, systems that improve planning efficiency and support standardized workflows may be particularly attractive within resource-constrained provider environments.

France

France generated USD 54 million in 2025 and is projected to account for 14.3% of European revenue by 2035. Demand is supported by coordinated cancer-care planning and investment in equipment renewal across comprehensive cancer centers and university hospitals. Structured technology assessment and centralized planning can make procurement more predictable, although suppliers must align with public-sector evaluation and reimbursement processes. This favors vendors able to demonstrate both clinical and operational value.

Italy

Italy accounted for 10.6% of European revenue in 2025 and is projected to reach USD 114 million by 2035. Regional health authorities and private oncology providers together create a distributed procurement landscape. Demand is likely to be shaped by the pace of modernization across regional health systems. Suppliers with flexible service models and strong local channel capabilities can be better positioned to address the market's fragmented purchasing structure.

Spain

Spain generated USD 27 million in 2025 and is projected to represent 7.2% of European revenue by 2035. Growth is tied to private hospital investment and regional public-sector replacement programs. The opportunity depends on continued modernization of radiotherapy infrastructure. Provider interest should be strongest where advanced treatment capability can improve referral positioning and support broader oncology service expansion.

Netherlands

The Netherlands accounted for 5.3% of European revenue in 2025 and is projected to reach USD 57 million by 2035. Its market profile is supported by a strong research and clinical-innovation environment in radiotherapy. The country's specialized centers can serve as reference sites for adaptive and image-guided treatment approaches. Such institutions can influence technology adoption beyond their own purchasing volume by generating clinical experience and training capability.

Asia Pacific Robotic Radiotherapy Market Analysis

Asia Pacific generated USD 378 million in 2025 and is projected to account for 28.0% of market revenue by 2035. The robotic radiotherapy market in the region combines mature premium-technology demand in Japan and South Korea with large-scale capacity expansion in China, India, and other developing healthcare systems. Commercial conditions vary widely across the region. Government-directed procurement, domestic manufacturing capability, private hospital investment, and specialist availability all influence the pace and technology mix of adoption.

China

China accounted for 42.9% of Asia Pacific revenue in 2025 and is projected to reach USD 461 million by 2035. Demand is supported by oncology-capacity expansion and modernization of radiotherapy equipment across a broad hospital base. Domestic manufacturers are becoming increasingly relevant in public procurement, while international suppliers retain opportunities in premium-tier hospitals and tertiary care settings. Regulatory, procurement, and localization requirements will remain important determinants of competitive success.

Japan

Japan generated USD 81 million in 2025 and is projected to account for 21.4% of Asia Pacific revenue by 2035. The market is characterized by sophisticated oncology providers and a strong orientation toward advanced radiotherapy modalities. Technology quality, clinical performance, and specialized treatment capability can outweigh simple acquisition-cost considerations. This supports demand for systems serving complex indications and for platforms integrated with high-value service and planning offerings.

India

India accounted for 10.6% of Asia Pacific revenue in 2025 and is projected to reach USD 114 million by 2035. The market is supported by growing cancer-care needs, private hospital expansion, and broader investment in oncology infrastructure. The opportunity is substantial but operationally demanding. Providers must balance advanced technology ambitions with affordability, workforce development, and geographic access, creating demand for scalable systems and service models.

South Korea

South Korea generated USD 54 million in 2025 and is projected to account for 14.3% of Asia Pacific revenue by 2035. Comprehensive cancer-care coverage and a dense network of university hospitals support adoption of advanced radiotherapy capability. The market's clinical sophistication makes it receptive to technologies that improve precision and treatment adaptability. Domestic innovation activity also contributes to a competitive environment in which platform differentiation remains important.

Australia

Australia accounted for 7.1% of Asia Pacific revenue in 2025 and is projected to reach USD 77 million by 2035. A well-developed public health system and an active private oncology sector support demand for specialized radiotherapy capacity. Private oncology networks can create incremental opportunities for robotic radiosurgery and stereotactic platforms. Adoption will be influenced by how suppliers demonstrate clinical value alongside operational fit within dispersed care networks.

Latin America Robotic Radiotherapy Market Analysis

Latin America generated USD 67 million in 2025 and is projected to grow at an 11.10% CAGR (2026–2035). The robotic radiotherapy market in the region is driven by unmet cancer-care demand, expanding private-sector oncology investment, and public initiatives aimed at improving treatment access. Growth starts from a comparatively limited installed base, so deployment depends heavily on financing, import logistics, specialist capacity, and the ability of providers to sustain complex equipment. Mid-tier robotic and linac-based systems are likely to remain particularly relevant in early capacity-buildout phases.

Brazil

Brazil accounted for 59.7% of Latin American revenue in 2025 and is projected to reach USD 114 million by 2035. Its scale, urban private-hospital market, and significant oncology needs make it the region's central demand center. Private providers are likely to lead adoption of premium capability in major metropolitan areas, while public-system investment can broaden access over a longer cycle. Suppliers must navigate a market where clinical need is strong but procurement conditions vary substantially by provider and location.

Mexico

Mexico generated USD 14 million in 2025 and is projected to account for 19.8% of Latin American revenue by 2035. Private hospital development and public-sector modernization create a gradual basis for market expansion. Proximity to North American supply and distribution networks can support equipment access, but adoption remains dependent on financing capacity and provider readiness. The most compelling opportunities are likely to arise in high-acuity urban oncology settings.

Argentina

Argentina accounted for 10.4% of Latin American revenue in 2025 and is projected to reach USD 19 million by 2035. Its clinical and academic capabilities provide a base for selective advanced-platform adoption. Macroeconomic volatility remains a material constraint on long-cycle capital procurement. Vendors that can support financing flexibility and maintain dependable service coverage may be better positioned to capture demand at leading centers.

Middle East & Africa Robotic Radiotherapy Market Analysis

Middle East & Africa accounted for 4.0% of market revenue in 2025 and is projected to reach USD 153 million by 2035. The robotic radiotherapy market is concentrated in Gulf countries investing in comprehensive cancer-care infrastructure, while much of Africa remains in an earlier phase of radiotherapy-capacity development. The region offers a mix of high-value, centrally funded projects and access-driven infrastructure needs. Growth depends not only on capital commitments, but also on workforce development, regulatory readiness, and the ability to maintain complex systems over their operating life.

Saudi Arabia

Saudi Arabia accounted for 37.0% of Middle East & Africa revenue in 2025 and is projected to reach USD 57 million by 2035. Centralized healthcare investment and the development of comprehensive cancer centers support demand for premium robotic radiotherapy platforms. National health-transformation priorities can enable large projects with clear clinical ambitions. Suppliers with established service networks, advanced clinical support, and the capacity to participate in long-term partnerships are likely to be advantaged.

UAE

The UAE generated USD 14 million in 2025 and is projected to account for 24.8% of Middle East & Africa revenue by 2035. Demand is linked to the development of high-acuity cancer-care services in major metropolitan centers. The market's concentration of private and public investment supports adoption of technologically differentiated systems. Competitive positioning will depend on clinical reputation, regulatory access, and the ability to support medical-tourism and local-care objectives.

South Africa

South Africa accounted for 13.0% of Middle East & Africa revenue in 2025 and is projected to reach USD 20 million by 2035. It has one of the region's more established radiotherapy environments, spanning public academic centers and private providers. The resulting market is bifurcated between constrained public-sector capacity and investment-capable private facilities. This creates an opportunity for suppliers that can address both advanced clinical requirements and the practical economics of equipment deployment.

Robotic Radiotherapy Market Share & Competitive Landscape

The robotic radiotherapy market share landscape is concentrated, with the top five companies collectively accounting for 81% of revenue in 2025. High entry barriers arise from clinical-validation requirements, regulatory clearances, installed-base service obligations, and the need to integrate hardware with planning, imaging, and workflow systems.

Varian Medical Systems (Siemens Healthineers)

Varian Medical Systems, a Siemens Healthineers company, held a 28% market share in 2025. Its competitive position is supported by a broad treatment-platform portfolio, installed-base depth, and the ability to participate in health-system contracts combining imaging, radiotherapy delivery, digital tools, and long-term services. The company's strategic strength lies in ecosystem selling rather than standalone equipment supply. Integrated offerings can make Varian especially relevant to large providers seeking coordinated modernization across diagnostic and therapeutic oncology workflows.

Elekta AB

Elekta held a 22% market share in 2025. The company's position is differentiated by its LINAC, MR-guided radiotherapy, radiosurgery, and software portfolio, allowing it to address providers pursuing both conventional and adaptive treatment capability. Elekta reported approximately USD 1.7 billion in net sales for fiscal 2024/25, underscoring the scale of its broader oncology technology business ^{[6]Elekta AB. "Annual Report 2024/25." ir.elekta.com}. Its opportunity rests on translating platform innovation and software integration into recurring customer relationships across hospital and academic treatment settings.

Accuray Incorporated

Accuray held an 18% market share in 2025. Its CyberKnife and Radixact/TomoTherapy platforms give the company a specialized position in robotic radiosurgery, helical delivery, and image-guided treatment workflows. Accuray reported USD 458.5 million in total net revenue for fiscal 2025 ^{[5]Accuray Incorporated. "Accuray Reports Fourth Quarter and Fiscal 2025 Financial Results." prnewswire.com}. The company's commercial progress depends on extending its installed-base service relationships while broadening its relevance in adaptive radiotherapy and high-precision treatment programs.

GE Healthcare

GE Healthcare participates principally through imaging simulation, dose-management, and broader radiotherapy workflow infrastructure. Its imaging installed base can create cross-selling opportunities at oncology providers seeking to connect simulation and treatment-planning capability. The company's role illustrates the importance of adjacent imaging and digital infrastructure in robotic radiotherapy procurement. Vendors with established provider relationships may gain influence even where they are not the primary treatment-system supplier.

Hitachi, Ltd.

Hitachi holds a specialized position in proton beam therapy and associated beam-delivery infrastructure. Its participation benefits from technical experience in particle therapy and from demand at advanced academic and specialty oncology centers. The company is most relevant where providers are evaluating proton systems as part of long-term, high-capital cancer-care infrastructure. Such projects require engineering credibility, lifecycle support, and the ability to work within complex facility-development timelines.

Other Companies

Brainlab, Ion Beam Applications, Mevion, Mitsubishi Electric, ReflexXion, Shinva, United Imaging, ViewRay, and ZAP each address specific portions of the market through treatment-planning software, compact proton systems, particle therapy, biology-guided treatment, domestic LINAC supply, MR-guided radiotherapy, or dedicated radiosurgery. Their competitive importance reflects the market's need for differentiated clinical capability, cost-sensitive alternatives, and specialized technology pathways rather than a single uniform treatment architecture.

Recent Industry Developments

Accuray Introduces Stellar™ Adaptive Radiotherapy Solution (September 2025)

Accuray launched its Stellar™ Solution at the ASTRO Annual Meeting in September 2025 as an adaptive radiotherapy offering initially directed at the U.S. market. The platform combines treatment delivery, imaging, motion management, and an adaptive-ready workflow, strengthening Accuray's effort to broaden its position beyond its established radiosurgery and helical-delivery franchises ^{[7]Accuray Incorporated. "Accuray Launches All-in-One Radiotherapy Solution with Advanced Capabilities Designed to Set a New Standard in Cancer Care." prnewswire.com}.

Siemens Healthineers and Prisma Health Expand Adaptive Radiotherapy Partnership (July 2025)

Siemens Healthineers and Prisma Health expanded their value partnership through an investment in Varian's Ethos adaptive radiotherapy system. The agreement demonstrates how health systems are using multi-year partnerships to link precision-radiotherapy capability with longer-term oncology service planning ^{[3]Siemens Healthineers. "Siemens Healthineers, Prisma Health Expand Value Partnership with $50 Million Investment in Radiation Therapy." siemens-healthineers.com}.